Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
about
Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide developmentPeptide and protein-based inhibitors of HIV-1 co-receptorsAnti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.Small neutralizing molecules to inhibit actions of the chemokine CXCL12.T140 blocks the SDF-1/CXCR4 signaling pathway and prevents cartilage degeneration in an osteoarthritis disease modelLow-molecular-weight CXCR4 ligands with variable spacers.HIV entry inhibitors and their potential in HIV therapyPET imaging of CXCR4 using copper-64 labeled peptide antagonist.Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay.The therapeutic potential of CXCR4 antagonists in the treatment of HIV.The intricate role of CXCR4 in cancer.Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC.Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imagingThe therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.Targeting protein-protein interactions by rational design: mimicry of protein surfacesImproved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infectionDrug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.Comparison of (18)F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression.Recent patents regarding the discovery of small molecule CXCR4 antagonists.Role of CXCR4 in HIV infection and its potential as a therapeutic target.Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).Differential Expression of Chemokine Receptors and their Roles in Cancer Imaging.Imaging agents for the chemokine receptor 4 (CXCR4).A future perspective on the development of chemokine receptor CXCR4 antagonists.Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes.Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?Molecular imaging probes derived from natural peptides.The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway.Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists.Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres.Update on the development of HIV entry inhibitors
P2860
Q28257799-2339663A-60D7-4CF1-92E0-24244DE60192Q30352117-8C07B373-5384-4885-B8B4-AEC1DDB5E25AQ31170483-86AE33F1-76E0-4427-A642-4737CA480B3AQ33343941-B0540183-A0CD-4C86-9ACA-465D79F8423AQ33585013-5DB1FB6E-351C-46F4-997B-B0391373D5C1Q34453685-7EA24F08-3919-43B4-BE64-558A1CFB42A9Q34595921-C86D63FE-05CD-476C-8144-E5735CE1FAE5Q34895626-FAB21450-C2B8-4993-A7BA-44204C545509Q34996334-58FCE0A3-3E3F-4E99-9D12-7BC0A0CBA3F3Q35056053-96059C79-E952-4B13-8FC7-1DDBC6080A57Q35067624-1CCB73C1-E822-48E9-BE68-049BC445EA40Q35116822-C4585C1E-F385-407F-8E65-2BA795877902Q35227508-BA550E83-3BDB-406D-A6DC-2D45F7482D81Q36318564-17A47EF1-A126-4DC4-B406-C2E65515BE6BQ36539868-FB5D1D94-F4E1-4143-9D51-0FE8E44693B4Q36760742-64791E25-0ED3-4881-B082-FBFF11C1635BQ36934918-40D788AC-CB85-4594-897D-EBBA58268838Q37351199-2B73D72A-7CCB-4D19-8092-922AF112DCEFQ37352728-2A42F061-464C-43E0-96CF-95B732D2EBA2Q37393337-00C2389F-461C-4BAA-A5FC-6126DC65D858Q37481233-E5A41FE7-D142-46C6-9872-38485EB3005EQ37772888-5AA6E296-2670-4AE6-845B-D39AC522A349Q38003847-0C8343A0-B202-493A-AD85-D670E723520AQ38015856-06942CA7-6694-47F6-A770-112D063F5754Q38022430-6E498334-08DE-4E0D-8113-800FE8F2D69EQ38089173-A4E59AB4-DA79-4EC8-B27E-A5AD6D0C965FQ38539666-72B8713A-E01A-4C6A-9289-176059A2720BQ38542935-1EC67B95-29B7-44C7-8CCD-7622E985FDA1Q38574172-CB94DFBB-9733-46A1-B8ED-117536BFD36CQ38680670-8B5FB31D-5947-4454-B330-1E5A7F86BCD2Q38748846-ADA0976F-7B5C-420C-A414-3E678A49FE21Q39029310-C173BCA2-D880-4F2C-88A0-E3E14F77F8E6Q39157622-40D8A014-D384-4B41-AC58-5DDE9FA7FAB4Q39533175-CE11CC08-917D-407C-8CEE-FD7C49F175E1Q39749640-F98DBD65-4E4F-4528-AB4C-2FD98448A35FQ58388992-BD2326F7-BF5A-4109-9B57-2EE0AD2DDC95
P2860
Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacophore identification o ...... very high selectivity indexes.
@ast
Pharmacophore identification o ...... very high selectivity indexes.
@en
type
label
Pharmacophore identification o ...... very high selectivity indexes.
@ast
Pharmacophore identification o ...... very high selectivity indexes.
@en
prefLabel
Pharmacophore identification o ...... very high selectivity indexes.
@ast
Pharmacophore identification o ...... very high selectivity indexes.
@en
P2093
P1476
Pharmacophore identification o ...... very high selectivity indexes.
@en
P2093
Kanamoto T
Nakashima H
Tamamura H
Yamamoto N
P304
P356
10.1016/S0960-894X(00)00535-7
P407
P577
2000-12-01T00:00:00Z